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Sleep apnea syndrome is increasingly recognized in
peritoneal dialysis patients; however, its prognostic
implication in this population is unknown. To study this,
we prospectively followed the clinical outcome of 93
peritoneal dialysis patients with baseline polysomnography.
Of these, 51 were diagnosed with the syndrome defined
by an apnea–hypopnea index (AHI) of at least 15 per hour.
During a median follow-up of 41 months, there were
30 deaths, of which 17 were due to cardiovascular causes.
Kaplan–Meier analysis for the entire follow-up period
indicated that patients with sleep apnea at baseline had
significantly higher all-cause and cardiovascular mortality
during follow-up than those without. Minimal nocturnal
saturation and desaturation indices were predictors of
mortality and cardiovascular events at univariate analysis.
Multivariable Cox regression analysis identified significant
sleep apnea syndrome at baseline as an independent
predictor of increased all-cause mortality independent of age,
male gender, and diabetic status. Further, an absolute
increase in the AHI was associated with an incremental risk
of cardiovascular events. Thus, sleep apnea syndrome,
detected at the start of peritoneal dialysis, is a novel risk
predictor for subsequent mortality and cardiovascular events.
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Sleep disturbances are highly prevalent among dialysis
patients compared with the general population.1,2 Among
the various sleep disturbances, sleep apnea is being increas-
ingly recognized in dialysis patients.3 Although sleep-
disordered breathing occurred in 2–4% of the middle-aged
Chinese population,4,5 its prevalence is uniformly over 50%
among Chinese subjects on peritoneal dialysis as gauged
by self-reported questionnaires6,7 or by the more objective
method of overnight polysomnographic measurement.8
Unruh et al.9 recently reported that patients on hemodialysis
had a fourfold increase in prevalence of sleep-disordered
breathing and nocturnal hypoxemia even after adjusting
for cardiovascular morbidity and diabetic status, compared
with participants from the Sleep Heart Health Study matched
for age, gender, body mass index, and race, indicating
that the pathophysiology of sleep apnea is uniquely
associated with the development of chronic renal failure.
Several studies have addressed the effect and importance of
sleep apnea on quality of life of peritoneal dialysis patients
and showed that sleep problems severely affect their
general health and psychosocial well-being.10,11 However,
it remains unknown whether sleep apnea in peritoneal
dialysis patients is a risk factor for mortality and morbidity,
in particular cardiovascular events as occurs with the
nondialysis population.12
We have embarked on the ‘Sleep apnea in PD patients’
program since 2001 to study sleep apnea in Chinese
peritoneal dialysis patients, focusing on the pathogenetic
mechanisms of sleep apnea during uremia.8,13 We prospec-
tively collected baseline polysomnographic data on a
cohort of Chinese peritoneal dialysis patients soon after
the commencement of peritoneal dialysis and followed their
clinical outcome longitudinally. In this study, we hypo-
thesize that the severity of sleep apnea, reflected by the
apnea-hypopnea index (AHI) or the number of apneic
or hypopneic events per hour of sleep, is a polysomno-
graphic marker that predicts all-cause mortality and
cardiovascular events in the chronic peritoneal dialysis
population.
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RESULTS
From 2001 onward, 93 incident patients were recruited into
our ‘Sleep apnea in PD patients’ program and underwent at
least one overnight polysomnography (PSG) measurement
at the commencement of PD. The baseline demographic,
clinical, and biochemical parameters are summarized
in Table 1. The median AHI of the entire study cohort was
21.7/h (interquartile range 3.0–48.2). The prevalence of
significant sleep apnea (AHI X15/h) was 55% (n¼ 51).
The median AHI for patients with AHI o15 and X15/h is
shown in Figure 1. The key PSG parameters were shown in
Table 2. Analysis of the apneic components showed that
obstructive pattern was the predominant form of apnea. The
median central and obstructive apnea indices were 0.9 and
14.9 episodes/h, respectively (Table 2). Six patients (6.2%)
had predominant central apnea, defined as a central apnea
index (CAI) of X15/h and CAI/total AHI 450%. After a
median follow-up of 41 months (interquartile range, 24–49),
53 patients (56.9%) developed one or more cardiovascular
events, in whom 20 (21.5%), 9 (9.7%), 11 (11.8%), and 13
(14.0%) patients had 1, 2, 3, and 43 episodes, respectively.
The first fatal or nonfatal cardiovascular event was ischemic
heart disease in 7, congestive heart failure or fluid overload
in 29, arrhythmia in 3, poorly controlled blood pressure
requiring hospitalization in 8, cerebrovascular event in 4, and
peripheral vascular disease in 2 patients.
Thirty (32.2%) patients had died, 13 (13.9%) received
kidney transplantation, and 5 (5.3%) were transferred
to permanent hemodialysis during follow-up. Among the
30 deaths, 17 (56.6%) were due to cardiovascular events
(including ischemic heart disease in six, congestive heart
failure in three, arrhythmia in one, peripheral vascular
disease in one, cerebrovascular accident in two, and sudden
death in four patients), and 13 (43.3%) were due to other
causes (including peritonitis in four, pneumonia in two,
other infections in five, and termination of dialysis because of
ill-health in two patients).
During the follow-up period, 5 in the group with baseline
AHI o15/h vs 25 patients with baseline AHI X15/h had
died, and the all-cause mortality was 5.4 vs 26.9%,
respectively (P¼ 0.015, Figure 2). The Kaplan–Meier esti-
mates for all cardiovascular event-free survival according to
the AHI cutoff of 15/h was shown in Figure 3. Patients with
baseline AHI X15/h took significantly shorter time to
develop more cardiovascular events than those with AHI
o15/h (P¼ 0.001). When patients were analyzed according
to whether they lived or died during follow-up, the baseline
AHI was significantly higher in those who died (P¼ 0.0001,
Figure 4). Similarly, when patients were stratified according
to whether they developed a cardiovascular event during
follow-up, patients with one or more events had significantly
higher baseline AHI (P¼ 0.006, Figure 5).
The unadjusted and fully adjusted hazard ratios of AHI
X15/h and other factors in relation to all-cause and all fatal
and nonfatal cardiovascular events were shown in Tables 3
and 4. For all-cause mortality, both age and AHIX15/h were
important predictors in both the univariate and the fully
adjusted multivariable Cox regression models. The fully
adjusted hazard ratio of AHI X15/h was 1.72 (95% CI,
1.03–2.88; P¼ 0.037). Minimal nocturnal oxygen saturation
was predictive of mortality in the univariate model, but was
removed during multivariate analysis. Also at univariate
analysis, both minimal oxygen saturation and desaturation
index predicted cardiovascular events. However, both vari-
ables were subsequently removed when introduced into the
Cox model. For fatal and nonfatal cardiovascular events, age,
AHI, and diabetes mellitus stood out in the fully adjusted
multivariable Cox regression models to be significant
predictors. The hazard ratio for every unit increase in AHI
by 1 episode/h was 1.02 (95% CI, 1.01–1.03; P¼ 0.003).
Other covariates known to affect cardiovascular morbidity
including serum albumin, calcium, phosphate, and hemo-
globin levels were not predictive of all-cause or cardiovas-
cular mortality in the present cohort.
DISCUSSION
The presence of significant sleep apnea at baseline is
associated with vascular risk factors and with substantial
cardiovascular morbidity and mortality in epidemiological
studies.14 In addition, it is clearly associated with increased
risks for stroke and death in the nondialysis population.
Among over 1000 subjects aged 50 or more, the presence of
even mild obstructive sleep apnea (AHI X5/h) constituted a
nearly twofold increase in risk even after adjustment for
demographic and clinical characteristics and smoking
habit.12 In the hemodialysis population, nocturnal hypox-
emia, a key indicator of sleep-disordered breathing, is a
strong predictor for incident cardiovascular complications.15
However, data are lacking as to whether the sleep apnea
syndrome may constitute equivalent risks in the peritoneal
dialysis population.
In this observational cohort study, we reported for the first
time that baseline AHIX15/h is an independent predictor of
subsequent all-cause mortality and cardiovascular morbidity
independent of other cardiovascular risk factors on extended
follow-up. We used an AHI cutoff of 15/h, which is in line
with previous studies reporting sleep apnea in peritoneal
dialysis patients,8,13 and which reflects moderate sleep
apnea in the nondialysis population.16 In terms of mortality,
baseline AHI X15/h constituted a 1.7-fold increase in risk
after adjustment for age, sex, and diabetic status. For
cardiovascular event-free survival, absolute AHI posed an
increased risk and diabetes also stood out as an independent
risk factor. This is not surprising given the association
between diabetes and cardiovascular morbidity. Apart from
AHI, minimal nocturnal oxygen saturations as well as the
desaturation index were predictive of cardiovascular events at
univariate analysis, which is in keeping with previous
report15 of the importance of oxygen saturation in this
regard. However, mean nocturnal oxygen saturation did
not predict cardiovascular events. This may be related to the
differences in the two cohorts of study subjects: in the study
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Demographic and clinical parameters
Age (years) 55.3±14.5 52.3±16.3 57.9±12.5 0.063
Percentage male (%) 51.6 40.5 60.8 0.062
Dialysis vintage (months) 9.8±10.8 7.6±10.1 11.7±11.2 0.071
Body mass index (kg/m2)c 23.4±3.7 22.8±3.7 24±3.6 0.116
Neck circumference (cm) 35.5±3.7 35.0±5.2 35.9±1.5 0.231
Neck-height ratio 0.224±0.026 0.222±0.035 0.226±0.017 0.466
Underlying renal disease
Diabetes mellitus 42 (45.2%) 14 (33.3%) 28 (54.9%) 0.060
Unknown 19 (20.4%) 6 (14.3%) 12 (23.5%) 0.302
Chronic glomerulonephritis 18 (19.4%) 13 (31.0%) 5 (9.8%) 0.016
Others 15 (16.1%) 9 (21.4%) 6 (11.8%) 0.262
Cardiovascular risk factors
Diabetes mellitus (N) 42 (45.2%) 14 (33.3%) 28 (54.9%) 0.060
Systolic blood pressure (mmHg) 136±9 136±10 136±9 0.817
Diastolic blood pressure (mmHg) 82±7 82±7 81±7 0.906
Hypertension (N) 66 (71%) 31 (74%) 35 (69%) 0.828
No. of antihypertensive drugs 2.27±0.71 2.31±0.78 2.24±0.65 0.618
Fasting lipid profile
Total cholesterol (mmol/l) 5.31±0.44 5.35±0.42 5.27±0.51 0.444
LDL cholesterol (mmol/l) 3.78±0.49 3.78±0.45 3.77±0.53 0.894
HDL cholesterol (mmol/l) 1.05±0.16 1.08±0.15 1.03±0.17 0.107
Triglycerides (mmol/l) 2.40±0.21 2.42±0.22 2.38±0.21 0.389
Hemoglobin (g/dl) 8.5±1.5 8.4±1.5 8.7±1.5 0.322
Serum calcium (mmol/l) 2.32±0.2 2.31±0.18 2.34±0.22 0.441
Serum phosphate (mmol/l) 1.78±0.52 1.85±0.56 1.72±0.47 0.211
Serum Ca PO4 product (mmol2/l2) 4.12±1.21 4.23±1.16 4.03±1.25 0.440
Smoking habit (history of) 17 (18%) 7 (17%) 10 (19.6%) 0.792
Cardiovascular co-morbidities
History of cerebrovascular disease 7 (7.5%) 3 (7.1%) 4 (7.8%) 1.0
History of myocardial infarction/CHF 9 (9.6%) 3 (7.1%) 6 (11.7%) 0.506
History of peripheral vascular disease 4 (4.3%) 2 (4.7%) 2 (3.9%) 0.506
Dialysis-related indices
KT/Vurea (per week)
Peritoneal 1.54±0.60 1.47±0.64 1.60±0.57 0.327
Renal 0.51±0.50 0.52±0.49 0.51±0.52 0.919
Total 2.05±0.66 1.99±0.75 2.11±0.59 0.415
Creatinine clearance (l per week per 1.73m2 BSA)
Peritoneal 35.7±14.3 33.0±14.6 38.0±13.8 0.100
Renald 33.6±34.2 37.0±39.2 30.8±29.4 0.399
Total 69.3±30.8 69.9±36.5 68.8±25.4 0.866
PET (dialysate/plasma Cr conc at 4 h)e 0.66±0.11 0.67±0.11 0.66±0.10 0.583
High transporter (0.82–1.03) 7 5 2
High average transporter (0.66–0.81) 36 15 21
Low average transporter (0.5–0.64) 46 20 26
Low transporter (0.34–0.49) 4 2 2
Body water compositionf
Total body water (l) 35.1±6.8 33.9±7.1 36.5±6.3 0.158
Extracellular water (l) 17.4±3.2 16.8±3.4 18.1±3.0 0.134
Intracellular water (l) 17.7±3.8 17.1±3.9 18.4±3.6 0.207
Hydration fraction (%) 63.6±8.0 62.1±7.4 65.4±8.4 0.129
Normalized protein catabolic rate (g/kg per day)g 1.09±0.41 1.08±0.44 1.10±0.40 0.798
Serum albumin (g/l) 34.8±5.0 36.2±4.2 34±5.3 0.056
Number on erythropoietin 52 (56%) 22 (52%) 30 (59%) 0.679
Abbreviations: AHI, apnea-hypopnea index; BSA, body surface area; Cr, creatinine; conc, concentration; CHF, congestive heart failure; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
aPlus–minus values are means±s.d.
bFor comparisons between patients with AHI o and X15/h.
cAbdomen emptied.
dRenal creatinine clearance was calculated by averaging urea and creatinine clearance rates estimated from 24-h urine collections.
eAccording to the method of peritoneal equilibration test (PET) and classification of transport status by Twardowski.27
fData available from 54 subjects (29 with AHI o 15/h) and computed as previously described.8
gDerived from the Randerson formula.29
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by Zoccali et al.,15 the primary dialysis modality was HD
instead of PD. Moreover, diabetes was an exclusion criterion
in the HD study, whereas diabetes was present in up to 45%
of patients here.
In contrast, residual renal function, hemoglobin levels,
and serum calcium x phosphate product, which are
traditionally viewed as a strong predictor for survival did
not have any effect. This is likely due to the narrow spread of
the baseline values in these parameters among the two
groups. Furthermore, the observation of higher AHI values in
patients who subsequently died or developed one or more
cardiovascular events are in agreement with the increased
health risks observed in hemodialysis and nondialysis
populations. The predominance of obstructive over central
forms of apnea obviates the argument that baseline presence
of central apnea may be a confounder in the subsequent
survival analysis.
There are good reasons why obstructive sleep apnea
predisposes to cardiovascular complications in dialysis
patients. First, sleep apnea is characterized by repetitive
cycles of apnea, hypoxia, hypercapnia, and arousal.17,18
Nocturnal hypoxemia has been linked to elevated oxidative
stress, increased coronary calcification, development of
sympathetic hyperactivity, and subsequent left ventricular
hypertrophy in chronic hemodialysis patients.19,20 Increased
cardiac and peripheral adrenergic drive may explain why
sleep apnea and nocturnal hypoxemia have been associated
with left ventricular hypertrophy.21 In addition, sleep apnea is
linked to the development of accelerated atherosclerosis,
myocardial infarction, hypertension, and heart failure in the
general population.22,23 It is therefore not surprising
that over half of the deaths in our cohort were due to
cardiovascular events, and that cardiovascular event-free
survival was inferior in the group of subjects with significant
sleep apnea at baseline.
The main medical therapy for the sleep apnea syndrome is























Figure 1 |Median apnea-hypopnea indices (AHIs) for patients
with baseline AHI o15/h (N¼ 42) and AHI X15/h (N¼ 51).
Box, line across, and whiskers indicate first and third quartiles,
median, and range, respectively.







AHIa 21.7 (3, 48.1) 2.2 (0.4, 5.9) 46.1 (31.7, 63.6) o0.001
Central apnea indexa 0.9 (0, 6.0) 0 (0, 0.5) 4.8 (1.4, 12.6) o0.001
Obstructive apnea indexa 14.9 (2.4, 38.4) 2.2 (0.4, 5.6) 36.7 (22.5, 47.9) o0.001
Mixed apnea indexa 3.9 (0.5, 14) 0.8 (0, 2.6) 11.1 (3.5, 23.0) o0.001
Mean nocturnal SaO2
c 96.0 (94, 97) 96.3 (94.8, 97.5) 95.5 (94, 97) 0.195
Minimal nocturnal SaO2
c 86.5 (77, 90.5) 90 (86.8, 93) 80 (68, 88) o0.001
Desaturation indexa 12.9 (2.9, 38.6) 3 (1.8, 8.8) 32.3 (13.3, 49.2) o0.001
Abbreviation: AHI, apnea-hypopnea index.
aResults are expressed as median number of episodes (interquartile range)/h of total sleep time.
bFor comparisons between patients with AHI o and X15/h.























Figure 2 |Kaplan–Meier estimates of patient survival
according to baseline presence (apnea-hypopnea index (AHI)





































Figure 3 |Kaplan–Meier estimates of cardiovascular event-free
survival according to baseline presence (apnea-hypopnea
index (AHI) X15/h) or absence (AHI o15/h) of significant
sleep apnea.
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to reduce the risk of cardiovascular events.24 This study,
however, was not designed or powered to address adherence
to treatment or the effect of treatment on outcomes. Indeed,
only a minority of subjects have agreed to referral for
consideration of nocturnal continuous positive airway
pressurization (CPAP). The reluctance stems mainly from
the need to perform nocturnal fluid exchange and the
perceived additional discomfort of two systems of treatment
at bed time. Even among referred subjects, reduced
compliance with treatment may have had a role in the
failure of therapy to reduce the risk to baseline levels.
Furthermore, it is likely that many of our patients had had
untreated sleep apnea for years before the commencement
of peritoneal dialysis, resulting in a prolonged exposure to
cardiovascular risk. The median 41 months of follow-up
may not have been a sufficient length of time to derive
the potential cardiovascular therapeutic benefits even if the
affected subjects had all been provided with and adhered
to CPAP.
Several methodologic issues should be considered in
the interpretation of our results. First, the ascertainment of
cardiovascular outcome was not possible in all patients, as
data were tracked over a long period of time. Some patients
for whom death was reported as the outcome event may have
had a previous unreported cardiovascular event. The
consequences of this methodologic limitation are reduced
by an analysis that focuses on the combined end point of fatal
and nonfatal cardiovascular events, but it is nonetheless
possible that uncaptured events occurring much earlier in
patients who died would alter the time-dependent character
of the findings. A related issue involves possible nonfatal
episodes among patients who were alive but were not
hospitalized. Second, it is possible that residual confounding
factors affected our adjusted hazard ratios, in spite of our
attempts to control for major cardiovascular risk factors.






















With CV event Without CV event
Figure 5 |Box plots showing baseline apnea-hypopnea indices
(AHIs) in patients with one or more subsequent
cardiovascular events (N¼ 53) and those without (N¼ 40)
during follow-up. Box, line across, and whiskers indicate first and
























Figure 4 |Box plots showing baseline apnea-hypopnea indices
(AHIs) in patients who died (N¼ 30) and those who were alive
(N¼ 63) during follow-up. Box, line across, and whiskers indicate
first and third quartiles, median, and 10th and 90th percentiles,
respectively.
Table 3 |Multivariable Cox regression analysis for all-cause mortality
Covariate Unit change
Unadjusted hazard
ratio (95% CI) P
Adjusted hazard
ratioa (95% CI) P
Demographic variables
Age +1 year 1.05 (1.02–1.09) 0.001 1.03 (1.01–1.05) 0.001
Gender (male) 1.18 (0.57–2.41) 0.659
Diabetes mellitus 2.53 (1.16–5.46) 0.020
Dialysis vintage + 1 month 1.0 (0.97–1.03) 0.998
Sleep-related parameters
AHI X 15/h 3.13 (1.19–8.20) 0.021 1.72 (1.03–2.88) 0.037
Mean SaO2 +1% 0.95 (0.85–1.053) 0.312
Minimal SaO2 +1% 0.97 (0.95–1.00) 0.036
Desaturation index +1 episode/h 1.01 (1.00–1.02) 0.114
Biochemical parameters
Residual CrCl +1 l per week per 1.73m2 0.99 (0.98–1.0) 0.403
Hemoglobin +1 g/dl 0.97 (0.91–1.04) 0.420
Serum albumin +1g/l 0.96 (0.88–1.04) 0.296
Ca PO4 product +1mmol2/l2 1.02 (0.74–1.41) 0.886
Abbreviation: AHI, apnea-hypopnea index.
aAdjusted for age, gender, diabetic status, dialysis vintage, residual creatinine clearance (CrCl), and minimum nocturnal oxygen saturation (SaO2) on recruitment.
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all possible confounders, although attempts were made to
correct for over-fitting. Nevertheless, we believe this is to date
the largest peritoneal dialysis cohort with baseline PSG data
and long-term longitudinal follow-up of clinical outcome.
In conclusion, sleep apnea syndrome detected at the outset
of peritoneal dialysis is significantly associated with the risk
of death from any cause and cardiovascular events, and this
association is independent of other risk factors, including age
and diabetes mellitus. Increased severity of the syndrome is
associated with an incremental risk of cardiovascular
morbidity. The assessment for the possibility of significant
sleep apnea through questionnaire with a view to further PSG
measurement should be considered as part of the routine
cardiovascular monitoring in chronic peritoneal dialysis
patients to identify those who have significant sleep apnea
and are at increased risk for subsequent cardiovascular
morbidity for timely intervention.
PATIENTS AND METHODS
Patients
The study protocol was fully reviewed and approved by the
clinical research ethics committee and Institutional Review
Boards of all participating institutions. Since 2001, consent-
ing subjects who participated in the ‘Sleep apnea in PD
patients’ program and had undergone at least one PSG
measurement were enrolled for analysis. All subjects must be
deemed clinically euvolemic with serum sodium between 135
and 145 mmol/l before undergoing overnight PSG. Exclusion
criteria included patients with underlying malignancy,
chronic structural heart disease, chronic obstructive pul-
monary disease, or bronchiectasis that required more than
one hospitalization per year, chronic liver disease, and active
autoimmune disorders. In addition, patients with primary or
known sleep apnea or pulmonary diseases or other illnesses
that may cause sleep apnea independently of chronic renal
failure, patients who were unable to cooperate or give consent
were also excluded. The recruitment flow diagram is shown
in Figure 6.
Dialysis protocol
A ‘PD-first’ policy is generally adopted in Hong Kong. On
initiation of dialysis, the particular PD system used was solely
the choice of the patient after they had received detailed
information. In general, patients performed 3–4 daily







Age + 1 year 1.04 (1.02–1.06) o0.001 1.03 (1.00–1.06) 0.04
Gender (male) 1.70 (0.98–2.95) 0.057
Diabetes mellitus 3.64 (2.05–6.45) o0.001 2.77 (1.46–5.26) 0.002
Dialysis vintage + 1 month 1.0 (0.98–1.03) 0.825
Sleep-related parameters
AHI X15/h 2.72 (1.51–4.93) 0.001
AHI +1/h 1.02 (1.01–1.03) o0.001 1.02 (1.01–1.03) 0.003
Mean SaO2 +1% 0.99 (0.94–1.03) 0.531
Minimal SaO2 +1% 0.97 (0.95–0.987) 0.001
Desaturation index +1 episode/h 1.019 (1.009–1.03) 0.001
Biochemical parameters
Residual CrCl +1 l per week per 1.73m2 0.99 (0.98–1.0) 0.144
Hemoglobin +1 g/dl 0.84 (0.70–1.01) 0.070
Serum albumin +1g/l 0.95 (0.89–1.01) 0.092
Ca PO4 product +1mmol2/l2 1.11 (0.88–1.39) 0.382
Abbreviation: AHI, apnea-hypopnea index.
aAdjusted for age, gender, diabetic status, and residual creatinine clearance (CrCl) on recruitment.
189 incident PD patients from 2001 to 2007
76 patients met exclusion criteria due to:
  Known sleep apnea (n=8)
  Severe COPD (n=7)
  Chronic liver disease (n =12)
  Active autoimmune disorders (n=2)
  Concomitant malignancy (n =2)
  Inability to cooperate (n=14)
  Refusal to give consent (n=31)   
Did not fit with availability of the sleep
laboratory (n =13)
 
113 eligible for recruitment
100 subjects underwent PSG
Patients with unanalyzable
polysomnographic data, but declined
to undergo re-evaluation (n=7) 
93 subjects with PSG data for 
analyses and follow-up 
Figure 6 | Flow diagram of patient recruitment process. COPD,
chronic obstructive pulmonary disease; PSG, polysomnography.
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exchanges of 2 l PDF using either UltraBag (Baxter Health-
care, Guangzhou, People’s Republic of China), StaySafe
or AndyDisk (Fresenius Medical Care, Bad Homburg,
Germany), or Gambrosol Trio (Gambro Lundia AB, Lund,
Sweden) system. Dialysis regimens were adjusted to achieve
euvolemia and a weekly KT/Vurea of 1.8–2.1.
Polysomnography
Comprehensive overnight PSG was performed in hospital
using Alice 3 or Alice 5 machine (Healthdyne, Atlanta, GA,
USA). Recordings included electroencephalogram, electro-
oculogram, submental electromyogram (EMG), bilateral
anterior tibial EMG, electrocardiogram, chest and abdominal
wall movement (respiratory effort) by inductance plethysmo-
graphy, airflow by a nasal pressure transducer (PTAF 2,
Pro-Tech, Woodinville, WA, USA), and finger pulse oximetry.
All variables were recorded continuously by a computerized
data-acquisition system and stored on an optical disk for
subsequent analyses.
All polysomnograms were scored manually by an
independent expert in sleep medicine without knowledge of
the mode of dialysis according to standard criteria.16,25,26
Apnea was defined as the cessation of airflow for 410 s, and
hypopnea was defined as a reduction of airflow ofX50% for
410 s plus an oxygen desaturation of X4%. The average
number of episodes of apnea and hypopnea per hour of sleep
(AHI) was calculated as the summary measurement of sleep-
disordered breathing. To assess oxygen saturation during
sleep, the following parameters were also manually scored:
(1) Mean nocturnal oxygen saturation (SaO2) while in REM
and non-REM sleep; (2) Minimal nocturnal SaO2; and (3)
Desaturation index, defined as the mean number of episodes
of SaO2 drop by X4% per hour of sleep.
Significant sleep apnea was arbitrarily defined as an AHI
of X15 events per hour of sleep as we previously reported
among PD subjects.8 Apnea were classified as central if there
was no chest and abdominal movement, or as obstructive if
they moved paradoxically, and as mixed if an initial absence
of ventilatory effort was followed by an obstructive apnea
pattern on resumption of effort. Cheyne–Stokes respiration
was defined as an episode of central apnea (or hypopnea)
alternating with breathing that had a pattern of cyclical
crescendo and decrescendo amplitude for at least three cycles
of not o60 s each. Periodic leg movements were defined
as four or more involuntary leg movements during sleep,
each lasting 0.5–5.0 s, with 5–90 s between movements.
Outcome measurements
The primary clinical outcomes evaluated were all-cause
mortality and the first episode of fatal and nonfatal cardio-
vascular morbidity in patients with and without significant
sleep apnea at baseline, defined as AHI X15/h. Cardiovas-
cular events included angina with electrocardiographic
changes of myocardial ischemia or infarction, heart failure,
fluid overload, acute pulmonary edema, arrhythmia, poorly
controlled blood pressure requiring hospitalization, transient
ischemic attack, thromboembolic or hemorrhagic stroke,
peripheral vascular disease, or sudden cardiac death. For
patients with multiple cardiovascular events, the time to
the first episode was taken for survival analysis. Secondary
outcomes included hemoglobin levels, nutritional status,
and transfer to another mode of renal replacement
therapy. Patients who underwent kidney transplantation or
transferred to hemodialysis were censored at the time of
transfer to alternative renal replacement therapy. If a patient
died within 3 months of transfer to hemodialysis, the death
was not censored because such mortality was considered to
reflect the health status during PD. The nature of cardiovas-
cular event was established by the attending physician, and
this information was retrieved from the online Clinical
Management System of the Hong Kong Hospital Authority.
During the period of follow-up, all deaths were accurately
recorded with the exact cause of death provided by the
attending physician.
Laboratory measurements and dialysis indices
Complete blood count, standard renal function tests includ-
ing serum bicarbonate levels were measured on the day of
PSG. Adequacy of dialysis was assessed at the steady state
using standard urea kinetic studies when patients were
established on PD for approximately 2 months. Total body
water (TBW) was derived using the Watson formula.
Residual renal function was estimated by 24-h urine
collection and expressed as renal Kt/V (total weekly urea
clearance) and weekly creatinine clearance. Peritoneal
membrane transport properties were assessed at the same
setting using standard peritoneal equilibration test.27 Body
water composition was measured before PSG in the evening
using multifrequency bioelectrical impedance analysis,
and TBW, extracellular water, and intracellular water, and
hydration fraction (TBW expressed as % body weight) were
computed according to previously described methods.8
Statistical analysis
Data are presented as means±s.d. All statistical analyses
were performed using SPSS v.16.0 (Statistical Package for the
Social Sciences Inc., Chicago, IL, USA) or GraphPad Prism
v.5.0 (GraphPad Software Inc., La Jolla, CA, USA) as
appropriate. All analyses were performed on an intention-
to-treat basis and included all patients who underwent
at least one PSG. Continuous characteristics at the start of
treatment were compared with Wilcoxon rank-sum tests.
Categorical groups were compared by the w2 test and Fisher’s
exact test, as appropriate. Cumulative patient and cardiovas-
cular event-free survival was calculated with the Kaplan–
Meier method, and comparisons between groups were made
with the log-rank test. For evaluation of the effect of
significant sleep apnea (AHI X15/h) in predicting the time
to all-cause mortality and the development of the first
episode of fatal or nonfatal cardiovascular event, factors
predictive of mortality and fatal and nonfatal cardiovascular
morbidities were identified with Cox regression analysis to
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deduce the hazard ratios and 95% confidence intervals.
Factors with Po0.25 on univariate analysis were entered
into the multivariable Cox regression model. A backward
elimination procedure with P40.05 to remove was
performed to identify independent predictors for the
development of all-cause mortality and cardiovascular events.
To correct for over-fitting as a result of the low total number
of deaths (n¼ 30), each regression coefficient obtained
from the Cox model was multiplied by a shrinkage factor
computed according to the method by Van Houwelingen
et al.28 All probabilities were two-tailed.
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